Virpax Pharmaceuticals, Inc. - FORM S-1 - EX-23.1 - CONSENT OF EISNERAMPERLLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE - September 9, 2021

Attached files

file filename
EX-10.23 - AGREEMENT FOR RENDERING OF RESEARCH SERVICES BETWEEN VIRPAX PHARMACEUTICALS, INC - Virpax Pharmaceuticals, Inc.ea147106ex10-23_virpaxpharma.htm
EX-10.16 - AGREEMENT FOR RENDERING OF RESEARCH SERVICES BETWEEN LIPOCURERX, LTD. AND VIRPAX - Virpax Pharmaceuticals, Inc.ea147106ex10-16_virpaxpharma.htm
EX-5.1 - OPINION OF LOWENSTEIN SANDLER LLP REGARDING THE VALIDITY OF THE COMMON STOCK BEI - Virpax Pharmaceuticals, Inc.ea147106ex5-1_virpaxpharma.htm
EX-1.1 - FORM OF UNDERWRITING AGREEMENT - Virpax Pharmaceuticals, Inc.ea147106ex1-1_virpaxpharma.htm
S-1 - REGISTRATION STATEMENT - Virpax Pharmaceuticals, Inc.ea147106-s1_virpaxpharma.htm

Exhibit 23.1

 

We consent to the inclusion in this Registration Statement of Virpax Pharmaceuticals, Inc. on Form S-1 to be filed on or about September 9, 2021 of our report dated March 31, 2021, on our audits of the financial statements as of December 31, 2020 and 2019 and for each of the years then ended. We also consent to the reference to our firm under the caption “Experts” in this Registration Statement.

 

/s/ EisnerAmper LLP

 

EISNERAMPER LLP

Philadelphia, Pennsylvania

September 9, 2021